Biocon shares in focus after successful results of Yesintek in Phase 3
Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...
Here's why Biocon share price popped 3% in trade on March 5; details here
The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received ...
CNBCTV183d
Biocon Biologics partners with US non-profit co to make diabetes treatment cheaper for Americans
This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...
Biocon shares climb 1% on partnership with Civica to boost insulin aspart availability in the US
Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...
Pharmabiz3d
Biocon Biologics and Civica collaborate to expand insulin aspart access in the US
Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...
Biocon Biologics to supply Insulin Aspart drug substance to Civica for US market
Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.
Devdiscourse4d
Biocon Biologics ties up with Civica Inc to expand diabetes drug access in US
Biocon Biologics on Thursday said it has tied up with not-for-profit generic drug and pharmaceutical firm Civica, Inc to expand access and affordability of Insulin Aspart in the US.
CNBCTV186d
Biocon targets mid-teen revenue growth with new product pipeline
Siddharth Mittal, MD and CEO of Biocon said the company will launch Liraglutide in Europe in FY26 along with its partner, ...
PLI boost: Cancer patients can hope for affordable drugs in India
New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have ...
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...